DK1604203T3 - Fremgangsmåde til direkte bestemmelse af individuelle methotrexatmeta-bolitter - Google Patents

Fremgangsmåde til direkte bestemmelse af individuelle methotrexatmeta-bolitter

Info

Publication number
DK1604203T3
DK1604203T3 DK04716493.4T DK04716493T DK1604203T3 DK 1604203 T3 DK1604203 T3 DK 1604203T3 DK 04716493 T DK04716493 T DK 04716493T DK 1604203 T3 DK1604203 T3 DK 1604203T3
Authority
DK
Denmark
Prior art keywords
mtxpg
bolites
meta
methotrexate
determining
Prior art date
Application number
DK04716493.4T
Other languages
English (en)
Inventor
Russell Richerson
Thierry Dervieux
Original Assignee
Prometheus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Lab Inc filed Critical Prometheus Lab Inc
Application granted granted Critical
Publication of DK1604203T3 publication Critical patent/DK1604203T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK04716493.4T 2003-03-07 2004-03-02 Fremgangsmåde til direkte bestemmelse af individuelle methotrexatmeta-bolitter DK1604203T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/384,066 US6921667B2 (en) 2003-03-07 2003-03-07 Methods for direct detection of individual methotrexate metabolites
PCT/US2004/006312 WO2004081521A2 (en) 2003-03-07 2004-03-02 Methods for direct detection of individual methotrexate metabolites

Publications (1)

Publication Number Publication Date
DK1604203T3 true DK1604203T3 (da) 2010-03-01

Family

ID=32927184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04716493.4T DK1604203T3 (da) 2003-03-07 2004-03-02 Fremgangsmåde til direkte bestemmelse af individuelle methotrexatmeta-bolitter

Country Status (11)

Country Link
US (1) US6921667B2 (da)
EP (2) EP2148199A1 (da)
JP (1) JP2006520914A (da)
AT (1) ATE447174T1 (da)
AU (1) AU2004219711B2 (da)
CA (1) CA2517709C (da)
DE (1) DE602004023824D1 (da)
DK (1) DK1604203T3 (da)
ES (1) ES2335767T3 (da)
HK (1) HK1079571A1 (da)
WO (1) WO2004081521A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563590B2 (en) * 2002-08-30 2009-07-21 Cypress Bioscience Inc. Methods of quantifying methotrexate metabolites
US7582282B2 (en) * 2003-08-29 2009-09-01 Prometheus Laboratories Inc. Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
US20060286571A1 (en) * 2005-04-28 2006-12-21 Prometheus Laboratories, Inc. Methods of predicting methotrexate efficacy and toxicity
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
CA3033083A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
CA3090384A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
US20210213019A1 (en) * 2018-02-14 2021-07-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CN110320302A (zh) * 2019-07-23 2019-10-11 北京陆道培生物技术有限公司 快速测定甲氨蝶呤血药浓度的方法
CN111551659B (zh) * 2020-05-14 2022-11-18 上海大学 污水处理厂污泥中抗癌药物的快速检测分析方法
CN112415117A (zh) * 2020-12-04 2021-02-26 北京和合医学诊断技术股份有限公司 甲氨蝶呤的检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
US3989703A (en) 1974-03-22 1976-11-02 Institutul Oncologic Process of preparing N[p-{[(2,4-diamino-6-pteridyl)-methyl]N10 -methylamino}-benzoyl]-glutamic acid
US4106488A (en) 1974-08-20 1978-08-15 Robert Thomas Gordon Cancer treatment method
US3892801A (en) 1974-09-11 1975-07-01 American Cyanamid Co Method for preparing alkali salts of p-methylaminobenzoylglutamic acid
US4079056A (en) 1975-03-31 1978-03-14 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making pteridine compounds
US4057548A (en) 1975-11-11 1977-11-08 Jacek Wiecko Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor
US4067867A (en) 1976-03-30 1978-01-10 Jacek Wiecko Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
CH630380A5 (de) 1977-08-12 1982-06-15 Lonza Ag Verfahren zur herstellung von l-methotrexat.
US4136101A (en) 1978-02-03 1979-01-23 American Cyanamid Company Process for preparing dialkyl (p-aminobenzoyl) glutamates
US4306064A (en) 1980-03-25 1981-12-15 Ellard James A Synthesis of 2,4-diamino-6-hydroxymethylpteridine
US4421913A (en) 1980-04-23 1983-12-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester
US4374987A (en) 1980-08-14 1983-02-22 American Cyanamid Company Process for the preparation of high purity methotrexate and derivatives thereof
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US4662359A (en) 1983-08-12 1987-05-05 Robert T. Gordon Use of magnetic susceptibility probes in the treatment of cancer
FR2590255B1 (fr) 1985-11-19 1987-12-24 Rhone Poulenc Sante Procede de preparation de derives de la pteridine
US7563590B2 (en) * 2002-08-30 2009-07-21 Cypress Bioscience Inc. Methods of quantifying methotrexate metabolites

Also Published As

Publication number Publication date
EP1604203B1 (en) 2009-10-28
EP1604203A2 (en) 2005-12-14
HK1079571A1 (en) 2006-04-07
WO2004081521A2 (en) 2004-09-23
US20040175834A1 (en) 2004-09-09
JP2006520914A (ja) 2006-09-14
CA2517709A1 (en) 2004-09-23
EP1604203A4 (en) 2007-07-11
AU2004219711A1 (en) 2004-09-23
ATE447174T1 (de) 2009-11-15
ES2335767T3 (es) 2010-04-05
US6921667B2 (en) 2005-07-26
DE602004023824D1 (de) 2009-12-10
WO2004081521A3 (en) 2004-12-02
CA2517709C (en) 2011-11-15
EP2148199A1 (en) 2010-01-27
AU2004219711B2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
HK1079571A1 (en) Methods for direct detection of individual methotrexate metabolites
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
CY1109462T1 (el) Συνθεση και διαδικασια εκχυλιση του διαλυτη μεταλλων χρησιμοποιωντας τους παραγοντες εκχυλισης αλδοξιμη ή κετοξιμη
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도
DK2327792T3 (da) Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
DE60228557D1 (de) Candida-nachweis
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE463294T1 (de) Verfahren zur konzentration und reinigung von biologischen verbindungen
AR023736A1 (es) Ensayo de viabilidad para protozoarios formadores de esporocitos
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
CY1110138T1 (el) Προσδιορισμος υψηλης διεκπεραιωτικοτητας της δραστικοτητας lp-pla2
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE60334499D1 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
DK1560929T3 (da) Polynucleotider til amplifikation og detektion af chlamydia trachomatis og neisseria gonore
ATE524556T1 (de) Verfahren zur zyklischen nukleotid-bestimmung
BR0317612A (pt) Identificação, monitoração e tratamento de doença infecciosa e caracterização de condições inflamatórias relacionadas com doença infecciosa empregando perfis de expressão de gene
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
TR200501974T2 (tr) Geotekstillerin tespitinde tekstil yardımcı maddesinin uygulanması yöntemi ve tertibatı.
ATE440108T1 (de) Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilis
ATE415492T1 (de) Verfahren zum identifizieren von makrocyclischen polyketiden
DK1521848T3 (da) Fremgangsmåde til bestemmelse af kopitallet af en nukleotidsekvens
TR2023019112U5 (tr) Oksi̇jen ki̇ti̇
DK1616183T3 (da) Fremgangsmåde til påvisning af neurologiske forstyrrelser